The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma (MM). In previous trials, the combination was very active with over 80% response rate. This Phase III trial led to the approval of the elotuzumab in the USA, and demonstrated a 30% improvement in duration of remission, a higher overall response, and the combination also showed activity in high-risk MM patients, in particular the ones with 17p and (4;14) translocation. These results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
